Skip to main content
Login
Contact
Subscribe
Search form
Search
The Punxsutawney Spirit
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Local Guide
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
AbbVie
(NY:
ABBV
)
110.86
USD
-0.40 (-0.36%)
Official Closing Price
Updated: 7:52 PM EST, Jan 22, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Biotech Is Fueling An All-New Cannabis Boom
January 21, 2021
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Biotech Is Fueling An All-New Cannabis Boom
January 21, 2021
- FN Media Group Presents Safehaven.com Market Commentary
From
PR Newswire
Allergan Aesthetics and Allergan, an AbbVie Company, to Present 16 Neurotoxin Research Abstracts Across Multiple Therapeutic and Cosmetic Indications at the TOXINS 2021 Virtual Conference
January 15, 2021
- BOTOX® (onabotulinumtoxinA) and BOTOX Cosmetic® clinical data across multiple therapeutic and aesthetic indications
From
PR Newswire
Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma
January 13, 2021
From
GlobeNewswire News Releases
Allergan Aesthetics Enters Into Option to Acquire Cypris Medical
January 12, 2021
-- Agreement Includes Development of Xact Device, a Minimally-Invasive Alternative Option for Performing Face and Neck Lifts --
From
PR Newswire
Researchers Seek to Better Understand Psychedelics' Role in New Therapies
January 12, 2021
FinancialBuzz.com News Commentary
From
PR Newswire
AbbVie to Host Fourth-Quarter and Full-Year 2020 Earnings Conference Call
January 12, 2021
AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. AbbVie will host a live webcast of the earnings...
From
PR Newswire
Dragonfly Therapeutics Announces AbbVie Opt-In of TriNKET™ Immunotherapy Drug Candidate
January 12, 2021
Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced that AbbVie (NYSE: ABBV), has...
From
PR Newswire
Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
January 07, 2021
- A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab (600 mg or 1200 mg) achieved both primary endpoints, demonstrating statistically...
From
PR Newswire
AbbVie to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 06, 2021
AbbVie (NYSE: ABBV) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's executive leadership team will present virtually at 3:30 p.m....
From
PR Newswire
Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
January 05, 2021
- In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo...
From
PR Newswire
IMBRUVICA® (ibrutinib) U.S. Prescribing Information Updated to Include Long-Term Data for Waldenström's Macroglobulinemia (WM)
December 23, 2020
- Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab...
From
PR Newswire
CHMP Recommends the Approvals of RINVOQ™ (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
December 11, 2020
- Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS),...
From
PR Newswire
RINVOQ™ (upadacitinib) Achieved Superiority Versus DUPIXENT® (dupilumab) For Primary and All Ranked Secondary Endpoints in Phase 3b Head-to-Head Study in Adults with Atopic Dermatitis
December 10, 2020
- 71 percent of patients treated with upadacitinib achieved the primary endpoint of EASI 75 compared to 61 percent of patients treated with dupilumab at week 16 (p=0.006)[1]
From
PR Newswire
Upadacitinib (RINVOQ™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis
December 09, 2020
- Significantly more upadacitinib-treated (45 mg) patients achieved clinical remission (primary endpoint per Adapted Mayo Score) at week 8 compared to placebo in adults with moderate to severe...
From
PR Newswire
Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low
December 06, 2020
AbbVie (NYSE: ABBV), today announced results from a long-term integrated analysis of two Phase 3 clinical studies and additional pooled analysis evaluating the effect of IMBRUVICA (ibrutinib) based...
From
PR Newswire
AbbVie Presents Extended Follow-Up Data for Fixed Duration Treatment VENCLEXTA®/VENCLYXTO® (venetoclax) in Chronic Lymphocytic Leukemia (CLL)
December 05, 2020
- New five-year, follow-up analysis from the Phase 3 MURANO trial shows median progression-free survival (PFS) of 53.6 months in previously treated CLL patients taking VENCLEXTA/VENCLYXTO in...
From
PR Newswire
IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Shows High Rates of Disease-Free Survival One Year Post-Treatment in Previously Untreated Patients with Chronic Lymphocytic L
December 05, 2020
AbbVie (NYSE: ABBV) today announced new data from the Phase 2 CAPTIVATE (PCYC-1142) clinical trial evaluating IMBRUVICA® (ibrutinib) in combination with VENCLEXTA®/VENCLYXTO® (venetoclax) in previously...
From
PR Newswire
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
December 02, 2020
- Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases
From
PR Newswire
AbbVie and Frontier Medicines Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
December 02, 2020
- Multi-year, multi-program R&D partnership to deliver innovative treatment options across cancer and immunological diseases
From
PR Newswire
AbbVie to Host Virtual Immunology Strategic Update
December 01, 2020
AbbVie (NYSE: ABBV) will host a virtual immunology strategic update for investors on Monday, December 14, 2020 at 9:00 a.m. Central time. Richard A. Gonzalez, chairman of the board and chief executive...
From
PR Newswire
This Ancient Aztec Medicine Could Be A Gamechanger For Mental Health
November 30, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
This Ancient Aztec Medicine Could Be A Gamechanger For Mental Health
November 30, 2020
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary
From
PR Newswire
AbbVie to Present at the Evercore ISI Conference and Piper Sandler Healthcare Conference
November 24, 2020
AbbVie (NYSE: ABBV) will participate in the Evercore ISI Virtual HealthCONx Conference on Wednesday, December 2 at 1:40 p.m. CT and the Piper Sandler Virtual Healthcare Conference on Thursday, December...
From
PR Newswire
AbbVie Announces Expiration and Final Results of Registered Exchange Offers
November 18, 2020
AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the expiration and final results of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $30,000,000,000...
From
PR Newswire
Banking on the Next Blockbuster Drug
November 18, 2020
From
InvestorBrandNetwork
Allergan Aesthetics Celebrates Second Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day
November 16, 2020
NUMBER 1 SELLING PRODUCT OF ITS KIND CELEBRATES BOTH LOYAL AND NEW CONSUMERS WITH EXCLUSIVE OFFER ON NOVEMBER 18th
From
PR Newswire
AbbVie to Present at the Wolfe Research Healthcare Conference
November 12, 2020
AbbVie (NYSE: ABBV) will participate in the Wolfe Research Healthcare Conference on Thursday, November 19, 2020. Michael Severino, M.D., vice chairman and president, and Robert A. Michael, executive...
From
PR Newswire
On the Trail of Better Therapeutics for Depression
November 10, 2020
From
InvestorBrandNetwork
On the Trail of Better Therapeutics for Depression
November 10, 2020
NetworkNewsWire Editorial Coverage
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.